NxStage Extends Supply Agreement with B. Braun Medical Inc. to Include Streamline(R)...

NxStage Extends Supply Agreement with B. Braun Medical Inc. to Include
Streamline(R) Technology

LAWRENCE, Mass., June 1 /PRNewswire-FirstCall/ -- NxStage Medical, Inc.
(Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today
announced that its Medisystems in-center business has completed development of
the new Streamline blood tubing sets for use on the B. Braun Dialog(R) and
Dialog Plus hemodialysis systems in the U.S. In connection with this
development, NxStage and B. Braun have agreed to extend their supply agreement
under which NxStage will supply B. Braun with the new Streamline sets and B.
Braun will provide sales, marketing, and clinical support to its U.S.
customers.

"The launch of Streamline for the B. Braun machines broadens our relationship
and extends the value of our product portfolio to B. Braun's Renal Therapies
Division giving patients and providers greater access to NxStage's high
quality, value-added in-center offerings," said Jeffrey H. Burbank, President
and Chief Executive Officer of NxStage Medical. "Streamline's ability to
improve patient clearances and reduce cost is yet another example of NxStage's
ability to innovate and bring value in the form of both clinical benefits and
operational savings."

"We are pleased to broaden our relationship with NxStage by offering the
unique Streamline technology to our dialysis customers," stated Samuel Amory,
Vice President, B. Braun Medical Renal Therapies Division. "We look forward
to leveraging Streamline's benefits with our state-of-the-art Dialog
hemodialysis system and growing our business with NxStage."

NxStage's latest generation blood tubing set is the Streamline. Streamline
features an efficient and airless design intended to improve clinical and
economic performance. Streamline is designed to reduce dialysate flow,
dialyzer size, treatment time, minimize heparin and waste, and optimize dose
delivery, as measured in Kt/V. Streamline also includes NxStage's patented
LockSite(R) needleless access ports, which eliminate the need for sharp
needles or costlier guarded needles to be used with the tubing set during
dialysis.

About B. Braun
B. Braun is a leading manufacturer of infusion therapy and pain management
products with an environmentally-friendly focus. Guided by the company's
"Sharing Expertise(R)" philosophy, B. Braun addresses the critical issues of
infection prevention, medication safety and environmental responsibility by
promoting best practices that help clinicians reduce medication errors,
prevent healthcare-acquired infections (HAIs) and achieve sustainability
objectives.

Consistently recognized by Frost & Sullivan and KLAS for its medical
technology and support services, B. Braun employees share their knowledge with
colleagues and customers to improve working processes in hospitals and medical
practices and to enhance the safety of patients and healthcare professionals.
For more information, call 800-227-2862, e-mail B. Braun at
inquiry.us@bbraun.com or visit B. Braun at www.bbraunusa.com.

About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company,
headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and
markets innovative products for the treatment of ESRD and acute kidney
failure. For more information on NxStage and its products, please visit the
company's website at http://www.nxstage.com.

Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements contained in
this release that are not clearly historical in nature are forward-looking,
and the words "anticipate," "believe," "expect," "estimate," "plan," and
similar expressions are generally intended to identify forward-looking
statements. Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important factors including,
but not limited to, changes relating to customer demand for NxStage's
Streamline blood tubing sets and other factors that are discussed in NxStage's
filings with the Securities and Exchange Commission, including the Quarterly
Report on Form 10-Q for the quarter ended March 31, 2009. NxStage is under no
obligation to (and expressly disclaims any such obligation to) update or alter
its forward-looking statements, whether as a result of new information, future
events or otherwise.

Contact:
Kristen K. Sheppard, Esq.
VP, Investor Relations
978-332-5923
ksheppard@nxstage.com

SOURCE NxStage Medical, Inc.

Kristen K. Sheppard, Esq., VP, Investor Relations, NxStage Medical, Inc.,
+1-978-332-5923, ksheppard@nxstage.com